Cholangiocarcinoma: Current Knowledge and New Developments.
Cholangiocarcinoma: Current Knowledge and New Developments.
复制标题
胆管癌：当前的知识和新发展。
DOI：
10.5009/gnl15568
复制
发表时间：
2017-01-15
期刊：
影响因子：
3.4
通讯作者：
Blechacz B
中科院分区：
文献类型：
--
作者：
Blechacz B
胆管癌（CCA）是第二常见的原发性恶性肿瘤。尽管它在亚洲更为常见，但近几十年来其在欧洲和北美的发病率显着增加。 CCA 的预后很差。手术是唯一可能治愈的治疗方法，但大多数患者已处于晚期疾病，切除后复发很常见。在过去的二十年中，我们对这种恶性肿瘤的分子生物学的了解大大增加，诊断技术不断发展，并且已经建立了新的治疗方法。本综述讨论了不断变化的流行病学趋势，并概述了新发现的 CCA 病因学危险因素。此外，还讨论了分子发病机制以及病因和胆道位置对 CCA 突变景观的影响。本综述概述了 CCA 的诊断评估及其分期系统。最后，对新的治疗方案进行了严格的审查，并讨论了未来的治疗策略。
Cholangiocarcinoma (CCA) is the second most common primary malignancy. Although it is more common in Asia, its incidence in Europe and North America has significantly increased in recent decades. The prognosis of CCA is dismal. Surgery is the only potentially curative treatment, but the majority of patients present with advanced stage disease, and recurrence after resection is common. Over the last two decades, our understanding of the molecular biology of this malignancy has increased tremendously, diagnostic techniques have evolved, and novel therapeutic approaches have been established. This review discusses the changing epidemiologic trends and provides an overview of newly identified etiologic risk factors for CCA. Furthermore, the molecular pathogenesis is discussed as well as the influence of etiology and biliary location on the mutational landscape of CCA. This review provides an overview of the diagnostic evaluation of CCA and its staging systems. Finally, new therapeutic options are critically reviewed, and future therapeutic strategies discussed.